Switch theme
Sign up to access all valuation multiples
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
1969
105
LTM Revenue $21.9M
LTM EBITDA n/a
$47.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vaxart has a last 12-month revenue of $21.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vaxart achieved revenue of $28.7M and an EBITDA of -$54.9M.
Vaxart expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vaxart valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $7.4M | $28.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$72.1M | -$54.9M | XXX | XXX | XXX |
| EBITDA Margin | -978% | -191% | XXX | XXX | XXX |
| Net Profit | -$108M | -$82.5M | XXX | XXX | XXX |
| Net Margin | -1460% | -287% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vaxart's stock price is $0.
Vaxart has current market cap of $81.9M, and EV of $47.7M.
See Vaxart trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $47.7M | $81.9M | XXX | XXX | XXX | XXX | $-0.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vaxart has market cap of $81.9M and EV of $47.7M.
Vaxart's trades at 2.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Vaxart's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vaxart and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $47.7M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.9x | XXX | XXX | XXX |
| P/E | -1.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVaxart's NTM/LTM revenue growth is -78%
Vaxart's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Vaxart's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vaxart's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vaxart and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 289% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -191% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -270% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 72% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 259% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 331% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vaxart acquired XXX companies to date.
Last acquisition by Vaxart was XXXXXXXX, XXXXX XXXXX XXXXXX . Vaxart acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vaxart founded? | Vaxart was founded in 1969. |
| Where is Vaxart headquartered? | Vaxart is headquartered in United States of America. |
| How many employees does Vaxart have? | As of today, Vaxart has 105 employees. |
| Who is the CEO of Vaxart? | Vaxart's CEO is Mr. Steven Lo. |
| Is Vaxart publicy listed? | Yes, Vaxart is a public company listed on NAS. |
| What is the stock symbol of Vaxart? | Vaxart trades under VXRT ticker. |
| When did Vaxart go public? | Vaxart went public in 1990. |
| Who are competitors of Vaxart? | Similar companies to Vaxart include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vaxart? | Vaxart's current market cap is $81.9M |
| What is the current revenue of Vaxart? | Vaxart's last 12-month revenue is $21.9M. |
| What is the current EV/Revenue multiple of Vaxart? | Current revenue multiple of Vaxart is 2.2x. |
| What is the current revenue growth of Vaxart? | Vaxart revenue growth between 2023 and 2024 was 289%. |
| Is Vaxart profitable? | Yes, Vaxart is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
